Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-05Clinical Trial Results: A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS [Phase 3]
A Phase 3 study evaluating monthly long-acting GA Depot injections for efficacy, safety, and tolerability in relapsing-remitting multiple sc…
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Update: Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) [Phase 3]
Phase 3 trial comparing ABP 692 against Ocrevus (ocrelizumab) for relapsing-remitting multiple sclerosis (RRMS).
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Results: Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis [Phase 1]
Phase 1 clinical trial evaluating peptide-coupled red blood cells for relapsing-remitting multiple sclerosis has completed with posted resul…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
An exploratory trial on the timing of multiple sclerosis symptoms (NCT00919217) sponsored by the University of Louisville has been terminate…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial [Phase 2]
RC18 is being studied in relapsing-remitting multiple sclerosis in a Phase II trial. The study status is terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) [Phase 3]
Phase 3 clinical trial comparing ABP 692 to Ocrevus (ocrelizumab) in relapsing-remitting multiple sclerosis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis [Phase 4]
Phase 4 clinical trial update on ocrelizumab in relapsing-remitting multiple sclerosis, describing its effects on immune cells in lymph node…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: MS Relapses During COVID-19 Pandemic
A completed clinical trial studying relapses in multiple sclerosis during the COVID-19 pandemic.
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. [Phase 4]
A Phase 4 clinical trial evaluating the effect of ofatumumab in treatment-naïve, very early relapsing-remitting multiple sclerosis patients.…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
A completed non-interventional study evaluating ocrelizumab in participants with relapsing-remitting or primary progressive multiple scleros…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality [NA]
This clinical trial update notes that a study examining attentional and executive disorders in relapsing-remitting multiple sclerosis using …
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis [Phase 1]
Phase 1 trial evaluating fecal microbiota transplantation with FMP30 for relapsing-remitting multiple sclerosis has been terminated with res…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: MS Synchronous vs Asynchronous Exercise Study [NA]
This clinical trial update notes completion of a study comparing synchronous versus asynchronous exercise in people with Multiple Sclerosis,…
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: Effect of Probiotics on Relapsing-Remitting Multiple Sclerosis [NA]
A completed clinical trial sponsored by Cairo University evaluated the effect of probiotic therapy on relapsing-remitting multiple sclerosis…
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
Clinical trial update reporting the completion of a Special Drug-use Surveillance study for Kesimpta (ofatumumab) 20 mg subcutaneous injecti…
-
CLINICAL_TRIALS trial_result · 2025-11-25Clinical Trial Update: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis [Phase 3]
This Phase 3 study evaluates multiple doses of natalizumab administered subcutaneously in Japanese participants with Relapsing-Remitting Mul…
-
CLINICAL_TRIALS trial_result · 2025-10-23Clinical Trial Update: Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis [Phase 2]
A Phase 2 trial evaluating the safety and efficacy of PIPE-307 in relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis [Phase 2]
Phase 2 proof-of-concept trial of frexalimab (SAR441344) for relapsing-remitting multiple sclerosis; results have been posted, and the study…
-
CLINICAL_TRIALS trial_result · 2025-09-24Clinical Trial Update: Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks [Phase 4]
Phase 4 clinical trial evaluating whether an ABCG2 gene mutation influences teriflunomide exposure and safety in Chinese patients with relap…
-
CLINICAL_TRIALS trial_result · 2025-09-08Clinical Trial Update: A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
A completed real-world study in Germany evaluated how ozanimod is used, its effectiveness, and quality of life in participants with relapsin…
-
CLINICAL_TRIALS trial_result · 2025-07-25Clinical Trial Update: Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme [NA]
Completed clinical trial evaluating a computerised semi-autonomous at-home cognitive rehabilitation programme for people with relapsing-remi…
-
CLINICAL_TRIALS trial_result · 2025-07-20Clinical Trial Update: Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) [Phase 3]
Biogen's Phase 3 efficacy and safety study of BG00012 (dimethyl fumarate) in pediatric Relapsing-Remitting Multiple Sclerosis has completed.…
-
CLINICAL_TRIALS trial_result · 2025-07-15Clinical Trial Update: Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis [Phase 2]
Phase 2 study evaluating the effects of corticosteroids on asymptomatic gadolinium-enhancing lesions in Relapsing-Remitting Multiple Scleros…
-
CLINICAL_TRIALS trial_result · 2025-06-08Clinical Trial Update: Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis [Phase 2]
A Phase 2 clinical trial evaluating bazedoxifene acetate as a remyelinating therapy for multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Educational Kinesiology Program's Effect on Cognition, Manual Dexterity and Bimanual Coordination in MS Patients [NA]
A completed clinical trial update from Cairo University evaluating an Educational Kinesiology Program's effects on cognition, manual dexteri…